717 related articles for article (PubMed ID: 33938021)
21. Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
Bryant N; Malpeli N; Ziaee J; Blauwendraat C; Liu Z; ; West AB
Hum Mol Genet; 2021 Apr; 30(6):454-466. PubMed ID: 33640967
[TBL] [Abstract][Full Text] [Related]
22. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
23. LRRK2 links genetic and sporadic Parkinson's disease.
Kluss JH; Mamais A; Cookson MR
Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
[TBL] [Abstract][Full Text] [Related]
24. Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease.
Cui SS; Fu R; Du JJ; Lin YQ; Huang P; Gao C; Zhou HY; Chen SD
BMC Neurosci; 2021 Mar; 22(1):22. PubMed ID: 33771108
[TBL] [Abstract][Full Text] [Related]
25. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.
Blauwendraat C; Reed X; Krohn L; Heilbron K; Bandres-Ciga S; Tan M; Gibbs JR; Hernandez DG; Kumaran R; Langston R; Bonet-Ponce L; Alcalay RN; Hassin-Baer S; Greenbaum L; Iwaki H; Leonard HL; Grenn FP; Ruskey JA; Sabir M; Ahmed S; Makarious MB; Pihlstrøm L; Toft M; van Hilten JJ; Marinus J; Schulte C; Brockmann K; Sharma M; Siitonen A; Majamaa K; Eerola-Rautio J; Tienari PJ; ; Pantelyat A; Hillis AE; Dawson TM; Rosenthal LS; Albert MS; Resnick SM; Ferrucci L; Morris CM; Pletnikova O; Troncoso J; Grosset D; Lesage S; Corvol JC; Brice A; Noyce AJ; Masliah E; Wood N; Hardy J; Shulman LM; Jankovic J; Shulman JM; Heutink P; Gasser T; Cannon P; Scholz SW; Morris H; Cookson MR; Nalls MA; Gan-Or Z; Singleton AB
Brain; 2020 Jan; 143(1):234-248. PubMed ID: 31755958
[TBL] [Abstract][Full Text] [Related]
26. No association of DNM3 with age of onset in Asian Parkinson's disease.
Foo JN; Tan LC; Au WL; Prakash KM; Liu J; Tan EK
Eur J Neurol; 2019 May; 26(5):827-829. PubMed ID: 30133089
[TBL] [Abstract][Full Text] [Related]
27. Genetic and Environmental Factors Influence the Pleomorphy of
Chittoor-Vinod VG; Nichols RJ; Schüle B
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494262
[TBL] [Abstract][Full Text] [Related]
28. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
[TBL] [Abstract][Full Text] [Related]
29. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
30. LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
Kumari U; Tan EK
FEBS J; 2009 Nov; 276(22):6455-63. PubMed ID: 19804413
[TBL] [Abstract][Full Text] [Related]
31. Role of
Sadhukhan D; Biswas A; Bhaduri A; Sarkar N; Biswas A; Das SK; Banerjee TK; Ray K; Ray J
Indian J Med Res; 2020 Jun; 151(6):592-597. PubMed ID: 32719233
[TBL] [Abstract][Full Text] [Related]
32. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
33. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
34. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.
Bakshi R; Macklin EA; Logan R; Zorlu MM; Xia N; Crotty GF; Zhang E; Chen X; Ascherio A; Schwarzschild MA
Ann Neurol; 2019 Apr; 85(4):593-599. PubMed ID: 30761591
[TBL] [Abstract][Full Text] [Related]
35. Genetic Modifiers of Neurodegeneration in a
Lavoy S; Chittoor-Vinod VG; Chow CY; Martin I
Genetics; 2018 Aug; 209(4):1345-1356. PubMed ID: 29907646
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel variants in LRRK2 gene in patients with Parkinson's disease in Serbian population.
Janković MZ; Kresojević ND; Dobričić VS; Marković VV; Petrović IN; Novaković IV; Kostić VS
J Neurol Sci; 2015; 353(1-2):59-62. PubMed ID: 25899316
[TBL] [Abstract][Full Text] [Related]
37. Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
Heckman MG; Labbé C; Kolicheski AL; Soto-Beasley AI; Walton RL; Valentino RR; Brennan ER; Johnson PW; Baheti S; Sarangi V; Ren Y; Uitti RJ; Wszolek ZK; Ross OA
Parkinsonism Relat Disord; 2021 Feb; 83():22-30. PubMed ID: 33454605
[TBL] [Abstract][Full Text] [Related]
38. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease.
Liu J; Zhou Y; Wang C; Wang T; Zheng Z; Chan P
Parkinsonism Relat Disord; 2012 Feb; 18(2):140-3. PubMed ID: 21924942
[TBL] [Abstract][Full Text] [Related]
39. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
[TBL] [Abstract][Full Text] [Related]
40. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.
Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K
Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]